Assuming the concentration of BLyS-RCT-@ complex and the IgM/IgG ratio are surrogate biomarkers for clinical effects of RCT-@ , the dose-response relationship suggests @-@mg are pharmacodynamically effective doses in RCT-@ for RA patients , but the effect profile of @mg RCT-@ on IgM is similar to that of atacicept at pharmacodynamically effective but clinically ineffective doses .